Table 1

Demographics and baseline characteristics

iGlarLixi (n = 367)iGlar (n = 369)
Age, years59.6 ± 9.460.3 ± 8.7
Female, %55.051.5
Race, %
 White9292
 Black56
 Other32
 Hispanic
  Yes1818
  No8282
Body weight at baseline, kg87.7 ± 14.587.1 ± 14.8
BMI at baseline, kg/m231.3 ± 4.331.0 ± 4.2
Patients with BMI ≥30 kg/m2, %57.557.2
Duration of diabetes, years12.0 ± 6.612.1 ± 6.9
Duration of basal insulin treatment, years3.1 ± 3.13.3 ± 3.1
Basal insulin type at screening, %
 iGlar6465
 Detemir1315
 NPH2320
OAD use at screening, %
 None55
 Metformin4652
 Sulfonylurea44
 DPP-4 inhibitor11
 Metformin + sulfonylurea3732
 Metformin + DPP-4 inhibitor55
 Metformin + glinide11
HbA1c, %
 At screening*8.5 ± 0.78.5 ± 0.7
 At baseline8.1 ± 0.78.1 ± 0.7
FPG, mmol/L
 At screening*7.9 ± 1.88 ± 1.8
 At baseline7.3 ± 2.07.4 ± 2.1
  • Data are presented as the mean ± SD, or as indicated.

  • DPP-4, dipeptidyl peptidase 4.

  • Screening values are at week −6 or *week −8;

  • †baseline values are at week −1.